Aug 27, 2025
BioMarin to Participate in Upcoming Investor Conferences
Aug 04, 2025
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
Jul 22, 2025
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
Jul 01, 2025
BioMarin Announces Completion of Acquisition of Inozyme
Jun 24, 2025
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
May 16, 2025
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
May 12, 2025
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
May 01, 2025
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
Apr 02, 2025
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
Feb 24, 2025
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
Feb 19, 2025
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
Feb 05, 2025
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
Jan 13, 2025
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
Jan 06, 2025
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
Nov 16, 2024
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Oct 29, 2024
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Sep 04, 2024
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
Sep 04, 2024
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
Aug 29, 2024
BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
Aug 21, 2024
BioMarin Announces New R&D and Business Development Leadership